Emalex Biosciences reports data from Tourette syndrome therapy trial

Emalex Biosciences has reported data from the Phase IIb D1AMOND clinical trial of ecopipam in Tourette syndrome.

The multicentred, placebo-controlled, randomised, global trial involved over 150 children and adolescents with Tourette syndrome.